Heart failure & cardiomyopathies
Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non–vaccine-associated myocarditis within the prospective multicenter registry—“MYKKE”
Authors' conclusion
Course of COVID-19 vaccine-associated myocarditis in pediatric patients seems to be mild and differs from non-vaccine-associated myocarditis.
Study context
- Population
- Patients <18 years with myocarditis, MYKKE registry (PedMYCVAC substudy), July 2021–December 2022
- Participants
- 56 vs 108
- Exposure
- COVID-19 vaccine-associated vs non-vaccine-associated myocarditis
- VA-myocarditisn = 56
- NVA-myocarditisn = 108reference
- Outcome
- Clinical course of VA-myocarditis
Methodological detailsmulticentre, 15 centres
- Multicentre
- 15 centres
Main finding
As reported in the abstract
- No severe HF, transplantation or death observed
- At 9-month follow-up all were free of symptoms
- Residuals mostly residual late gadolinium enhancement on MRI
Observational data: associations, not effects.
Further findings
NVA- vs VA-myocarditis
- NVA-myocarditis more often had symptoms of HF
- P = 0.003
- NVA-myocarditis more often had arrhythmias
- P = 0.031
- NVA-myocarditis more often had LV dilatation
- P = 0.045
- NVA-myocarditis had lower left ventricular ejection fraction (LVEF)
- P < 0.001
- NVA-myocarditis more often had major cardiac adverse events
- P = 0.102
- Adjusted for various baseline characteristics
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Clinical course and follow-up of pediatric patients with COVID-19 vaccine-associated myocarditis compared to non–vaccine-associated myocarditis within the prospective multicenter registry—“MYKKE”. Am Heart J. Published 11 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →